Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
Oryzon announced today that Dr. Tamara Maes will present the latest advances of its LSD1 program in hematological malignancies at GTC’s 2nd Epigenetics in Drug Discovery conference in the session Drug Discovery in Epigenetics: on May 30-31 at the Hyatt Harborside in Boston, MA.
